
Harter and colleagues (Dec. 2 issue)1 report that cytoreductive surgery followed by chemotherapy resulted in longer overall survival than chemotherapy alone in patients with recurrent ovarian cancer. This conclusion relies on the assumption of noninformative censoring, meaning that censoring is unrelated to the risk of the event.2 Using reconstructed patient-level survival data,3 we found that the number of patients with data that were censored in the surgery group (23 patients, 11.2%) was higher than that in the no-surgery group (12 patients, 5.8%) at 24 months, representing an excess of 11 patients.
Like
Save
Share